[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621792":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Federico II University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Subjects with hyperlipidaemia under Alirocumab 300 mg treatment.",null,"Subjects with hyperlipidaemia",[13],"Drug: Praluent (Alirocumab)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Praluent (Alirocumab)","Alirocumab 300 mg injection",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Pasquale Perrone Filardi","CONTACT","+390817462224","fpperron@unina.it",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Federico II University of Naples, Department of Advanced Biomedical Sciences","RECRUITING","Naples","Napoli","80131","Italy","IT",{"type":36,"coordinates":37},"Point",[38,39],14.26811,40.85216,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":44,"investigatorFullName":22,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Professor","100621792","evaluation-of-adherence-persistence-and-efficacy-of-treatment-with-alirocumab-300mg-in-italy-100621792",false,"NCT07375225","Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy","Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy - The ALINET Registry","ALINET","Inclusion Criteria:\n\n\\- Patients under alirocumab 300mg treatment.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years o \\> 80 years;\n* Patients who refuse to participate and to sign informed consent.","ALL","18 Years","80 Years",{"count":58,"type":59},1500,"ESTIMATED","3 Years","OBSERVATIONAL","Evaluation of adherence, persistence and efficacy of treatment with alirocumab 300 mg in a real-life Italian population.",[64],"Hypercholesterolaemia","2026-01-21",{"date":67,"type":68},"2026-01-29","ACTUAL",{"date":70,"type":68},"2024-12-01",{"date":72,"type":59},"2027-12-01",{"name":5,"class":6},1]